CAS 1207456-01-6

Talazoparib

Description:

Talazoparib is a potent and selective inhibitor of poly (ADP-ribose) polymerase (PARP), primarily used in the treatment of certain types of cancer, particularly breast cancer associated with BRCA1 and BRCA2 mutations. It is classified as a small molecule drug and is known for its ability to interfere with DNA repair mechanisms, thereby enhancing the effectiveness of chemotherapy and radiation therapy in cancer cells. Talazoparib exhibits high affinity for PARP enzymes, leading to the accumulation of DNA damage in cancer cells, which ultimately triggers apoptosis. The compound is typically administered orally and has a favorable pharmacokinetic profile, allowing for effective systemic exposure. Its chemical structure includes a bicyclic core, contributing to its biological activity. Talazoparib has been evaluated in clinical trials, demonstrating significant antitumor activity and a manageable safety profile, making it a valuable option in targeted cancer therapy. As with any medication, monitoring for potential side effects and interactions is essential during treatment.

Formula: C₁₉H₁₄F₂N₆O

InChI: InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1

InChI key: InChIKey=HWGQMRYQVZSGDQ-HZPDHXFCSA-N

SMILES: CN1C([C@H]2C=3C4=C(N[C@@H]2C5=CC=C(F)C=C5)C=C(F)C=C4C(=O)NN3)=NC=N1

Synonyms:

• (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazin-3-one
• 3H-Pyrido[4,3,2-de]phthalazin-3-one, 5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-, (8S,9R)-
• 5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-Pyrido[4,3,2-de]phthalazin-3-one
• Bmn-673
• Bmn673
• Talazoparib
• Talzenna

Talazoparib

CAS: 1207456-01-6

Talazoparib

Purity: ≥95%

Molecular weight: 380.35g/mol

Ref: 54-BUP15386

(8S,9R)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1H-1,2,4-Triazol-5-Yl)-8,9-Dihydro-2H-Pyrido[4,3,2-De]Phthalazin-3(7H)-One

CAS: 1207456-01-6

(8S,9R)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1H-1,2,4-Triazol-5-Yl)-8,9-Dihydro-2H-Pyrido[4,3,2-De]Phthalazin-3(7H)-One

Purity: 98%

Molecular weight: 380.35g/mol

Ref: 54-PC108468

Talazoparib

CAS: 1207456-01-6

Formula: C₁₉H₁₄F₂N₆O

Purity: ≥ 97.0%

Color and Shape: White to off-white powder

Molecular weight: 380.35

Ref: 7W-GP3601

Talazoparib

CAS: 1207456-01-6

Talazoparib (LT-673) is a new-type PARP inhibitor (IC50: 0.58 nM), It similarly binds to PARP1/2 (Kis: 1.2/0.85 nM).

Formula: C₁₉H₁₄F₂N₆O

Purity: 97.02% - 99.92%

Color and Shape: Solid

Molecular weight: 380.35

Ref: TM-T6253

(8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazine-3-one

CAS: 1207456-01-6

Talazoparib is a small-molecule inhibitor of DNA methyltransferases (DMTs) and is currently being investigated for the treatment of platinum-resistant ovarian cancer. DMTs are enzymes that catalyze the transfer of methyl groups to the cytosine in DNA, which leads to changes in gene expression. Talazoparib has been shown to inhibit DMT1, DMT3, and DMT4 in vitro studies and was found to be minimally toxic to cultured cells and animals. This drug also exhibits anti-cancer activity by inhibiting mitochondrial membrane potential, which may lead to cell death via apoptosis or necrosis.

Formula: C₁₉H₁₄F₂N₆O

Purity: Min. 95%

Color and Shape: Off-White To Yellow Solid

Molecular weight: 380.35 g/mol

Ref: 3D-FF103545